In 2017, R&D productivity of the top-30 pharmaceutical companies had decreased for the first time since 2014, according to Catenion’s annual review of the sector. This trend continued into 2018, albeit with a lower magnitude as overall R&D productivity dropped by around 10% (vs. about 15% last year).
Yet again, the major driver is a decline in the metric that looks at pipeline value versus cumulative R&D spending...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?